Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Immunome's IM-1021 shows 53% response rate in early-stage B-cell lymphoma trial

By Public Technologies
  • Immunome will present initial Phase 1 results for IM-1021 in advanced B-cell lymphomas at ASH on December 14, 2026.
  • The experimental antibody-drug conjugate produced complete and partial responses in heavily pretreated patients, with responses across all tested dose levels.
  • Clinical activity included patients whose disease had progressed following T-cell redirecting therapies.
  • Serious treatment-emergent adverse events included low neutrophil counts, the most common severe event.
  • Dose optimization across multiple regimens remains ongoing, with updated results planned for the meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104589966) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.